Key regions: United Kingdom, Germany, France, South Korea, Italy
Sweden, like many other countries, is currently experiencing the effects of the COVID-19 pandemic. The COVID-19 Vaccines market in Sweden is developing in a certain way due to various reasons.
Customer preferences: Customers in Sweden have shown a high level of interest in getting vaccinated against COVID-19. This is mainly due to the government's efforts to encourage people to get vaccinated by providing free vaccines to all citizens and residents. Additionally, there is a high level of trust in the healthcare system, which has further increased the demand for vaccines.
Trends in the market: The COVID-19 Vaccines market in Sweden has seen a significant increase in demand for vaccines since the government started rolling out the vaccine program. This has led to an increase in the number of vaccine manufacturers and suppliers in the market. Additionally, the government has also started to allow private healthcare providers to administer the vaccine, which has further increased the availability of vaccines.
Local special circumstances: Sweden has a relatively small population compared to other European countries, which has made it easier for the government to roll out the vaccine program. Additionally, the country has a highly developed healthcare system, which has helped in the efficient distribution of vaccines. However, there have been concerns about the slow pace of the vaccine rollout, which has led to criticism from some quarters.
Underlying macroeconomic factors: The COVID-19 pandemic has had a significant impact on the Swedish economy, with many businesses struggling to stay afloat. However, the vaccine program has provided some hope for economic recovery, as it is expected to help in the gradual reopening of the economy. Additionally, the government has also provided financial support to businesses affected by the pandemic, which has helped to mitigate the impact of the crisis.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
